Kaletra, Lopinavir/Ritonavir News

Genetic background has a major impact on the risk of coronary artery disease for people with HIV, results of a large study published in the online edition of Clinical Infectious Diseases show.

The U.S. Food and Drug Administration has made changes to the label for the single-pill HIV antiretroviral combination therapy Atripla .

A ritonavir-boosted lopinavir -based regimen achieved a comparable rate of virologic suppression when compared to a non-nucleoside reverse transcriptase inhibitor -based regimen in HIV-infected Ugandan children at 48 weeks, with comparable immunological responses and adverse events, researchers reported at the ... Children on ART for more than two ... (more)

Tenofovir alafenamide fumarate or TAF , a new pro-drug of the widely used NRTI tenofovir, reaches cells harbouring HIV more easily than the older tenofovir disoproxil fumarate , allowing for similar antiviral efficacy with smaller doses and with ... Data from a large study into the safety of anti-HIV drugs suggest that the antiretrovirals tenofovir ... (more)

Several presentations at the recent 20th Conference on Retroviruses and Opportunistic Infections in Atlanta suggest that previous estimates of the proportion of people with HIV in the USA who are on antiretroviral therapy and with an undetectable viral ... A second-line antiretroviral regimen of lopinavir/ritonavir and raltegravir proved just as ... (more)